New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2013
09:19 EDTCUK, LCC, ING, CCL, CPWR, ARIA, ALUOn The Fly: Pre-market Movers
HIGHER: Alcatel-Lucent (ALU), up 9.4% following upgraded to Buy at Deutsche Bank... ING Group (ING), up 3.6% after upgrade at BNP Paribas... ARIAD (ARIA), up 6.5% after updating on R&D and commercial progress for a newly launched drug and one under development... Navidea Biopharmaceuticals (NAVB), up 7.8% after its Lymphoseek meets primary efficacy endpoint in trial... LOWER: Compuware (CPWR), down 2.1%, after warning its fourth quarter earnings and revenue are likely to sharply miss consensus estimates... US Airways (LCC), down 1.8% following downgrade to Neutral from Buy at Bank of America Merrill Lynch... Carnival (CCL), down 1.7% after its "Triumph" cruiseship reported to have broken loose from its dock in Alabama.
News For CPWR;LCC;ALU;CCL;CUK;ARIA;ING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:47 EDTARIAARIAD to receive $200M through syntehtic-royalty financing with PDL BioPharma
Subscribe for More Information
07:43 EDTARIAARIAD to receive up to $200M through Iclusig synthetic-royalty financing with PDL BioPharma
ARIAD Pharmaceuticals (ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig until PDL receives a fixed internal rate of return. ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms. ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer and to support brigatinib commercial readiness, as well as to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration. “This financing allows us to accelerate initiation of the front-line trial of brigatinib and to ensure launch readiness as early as possible, while retaining strategic flexibility with respect to partnering and long-term commercialization of brigatinib,” said Harvey J. Berger, M.D., chairman and CEO of ARIAD. “We are confident based on the latest clinical data on brigatinib and other ALK‐inhibitors, that brigatinib may be an important new cancer medicine for patients with ALK+ lung cancer. With the funding provided by this royalty transaction, we expect to start the front-line trial by early next year, ahead of our expected filing for initial marketing approval of brigatinib in patients with refractory ALK+ NSCLC.”
July 28, 2015
07:15 EDTCCLCarnival's Costa Cruises to build two new cruise ships
Subscribe for More Information
July 24, 2015
13:29 EDTALUAlcatel CEO says Nokia deal may close sooner than expected, Re/code reports
Subscribe for More Information
06:08 EDTALUNokia receives European Commission approval for Alcatel-Lucent acquisition
Nokia (NOK) announced that it has received approval from the European Commission for its pending acquisition of Alcatel-Lucent (ALU). The proposed transaction was notified to the European Commission on June 19, 2015 and was cleared today without conditions following a Phase 1 review. Approval by the European Commission follows previously disclosed antitrust clearances in Brazil and Serbia and the expiration of the antitrust review period in the United States. In addition, the parties confirmed today they have received further antitrust clearances from Albania, Canada, Colombia and Russia. Both companies will continue to cooperate with the remaining authorities to close their reviews as quickly as possible. The transaction remains subject to approval by Nokia shareholders, Nokia holding over 50.00% of the share capital of Alcatel-Lucent on a fully diluted basis upon completion of the public exchange offer, receipt of other regulatory approvals and other customary conditions. The transaction is expected to close in the first half of 2016.
July 23, 2015
12:54 EDTCUK, CCLCarnival to pay $405,000 in settlement with Justice Department
The Justice Department and Carnival announced a settlement agreement under the Americans with Disabilities Act to "advance equal access for individuals with disabilities who travel on cruise ships." Under the agreement, 42 existing ships, and 7 ships in various stages of design and construction, will be surveyed and remediated to comply with the ADA regulations. Carnival will pay a civil penalty of $55,000 to the United States and $350,000 in damages to individuals harmed by past discrimination.
08:39 EDTCCLCarnival to expand fleet in China from four to six ships in 2016
Subscribe for More Information
05:36 EDTCUK, CCLCarnival signs agreement with Port Authority of Barcelona for new terminal
Subscribe for More Information
July 21, 2015
12:01 EDTCCLRoyal Caribbean names Jim Berra Chief Marketing Officer
Royal Caribbean (RCL) has named Jim Berra Chief Marketing Officer. Jim will be responsible for all aspects of the cruise line's marketing program, including brand strategy and positioning, consumer and trade advertising, web and loyalty marketing, research, brand development and communications. Jim most recently served as senior vice president and Chief Marketing Office for Carnival Cruise Line (CCL) where he oversaw the company's advertising, public relations, customer marketing and digital efforts.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use